Zealand Pharma (CPSE:ZEAL) - Prezzo delle azioni, notizie e analisi

ZEAL Panoramica delle azioni

Zealand Pharma A/S, società di biotecnologie, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci a base di peptidi in Danimarca. Maggiori dettagli

ZEAL analisi fondamentale
Punteggio fiocco di neve
Valutazione	1/6
Crescita futura	5/6
Prestazioni passate	0/6
Salute finanziaria	4/6
Dividendi	0/6

Premi

Si prevede che gli utili cresceranno del 65.84% all'anno

Gli analisti concordano sul fatto che il prezzo delle azioni salirà di 50.6%

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Importanti vendite da parte di insider negli ultimi 3 mesi

Prezzo delle azioni volatile negli ultimi 3 mesi

Zealand Pharma A/S Concorrenti

Genmab

CPSE:GMAB

DKK 93.0b

Bavarian Nordic

CPSE:BAVA

DKK 14.6b

BioPorto

CPSE:BIOPOR

DKK 696.9m

H. Lundbeck

CPSE:HLUN B

DKK 41.5b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Zealand Pharma
Prezzi storici delle azioni
Prezzo attuale dell'azione	DKK 676.50
Massimo di 52 settimane	DKK 972.00
Minimo di 52 settimane	DKK 303.80
Beta	0.54
1Variazione di 1 mese	-15.86%
Variazione a 3 mesi	-24.07%
Variazione di 1 anno	115.31%
3Variazione a 3 anni	357.40%
Variazione a 5 anni	217.90%
Variazione dall'IPO	750.94%

Notizie e aggiornamenti recenti

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Nov 09

Recent updates

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 18

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Mar 17

Here's Why We're Watching Zealand Pharma's (CPH:ZEAL) Cash Burn Situation

Oct 03

Downgrade: Here's How Analysts See Zealand Pharma A/S (CPH:ZEAL) Performing In The Near Term

Aug 14

Rendimenti per gli azionisti

	ZEAL	DK Biotechs	DK Mercato
7D	-22.9%	-14.0%	-6.0%
1Y	115.3%	-11.5%	4.2%

Ritorno vs Industria: ZEAL ha superato il Danish Biotechs che ha restituito -11.5 % nell'ultimo anno.

Rendimento vs Mercato: ZEAL ha superato il mercato Danish che ha restituito 4.2 % nell'ultimo anno.

Volatilità dei prezzi

Is ZEAL's price volatile compared to industry and market?
ZEAL volatility
ZEAL Average Weekly Movement	6.4%
Biotechs Industry Average Movement	7.9%
Market Average Movement	4.2%
10% most volatile stocks in DK Market	10.4%
10% least volatile stocks in DK Market	2.5%

Prezzo delle azioni stabile: Il prezzo delle azioni di ZEAL è stato volatile negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 6% ) di ZEAL è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni Danish.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1997	298	Adam Steensberg	www.zealandpharma.com

Zealand Pharma A/S, società di biotecnologie, è impegnata nella scoperta, nello sviluppo e nella commercializzazione di farmaci a base di peptidi in Danimarca. Ha un portafoglio di farmaci incentrati su malattie gastrointestinali e metaboliche e su altre aree patologiche speciali con esigenze mediche insoddisfatte. L'azienda offre Dasiglucagon, una siringa o un autoiniettore monouso per il trattamento dell'ipoglicemia grave, e i sistemi di pancreas artificiale bi-ormone Dasiglucagon, contenenti insulina e dasiglucagone.

Zealand Pharma A/S Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Zealand Pharma con la sua capitalizzazione di mercato?
ZEAL statistiche fondamentali
Capitalizzazione di mercato	DKK 47.79b
Guadagni(TTM)	-DKK 1.05b
Ricavi(TTM)	DKK 76.87m

621.7x

Rapporto P/S

-45.4x

Rapporto P/E

ZEAL è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
ZEAL Conto economico (TTM)
Ricavi	DKK 76.87m
Costo del fatturato	DKK 704.13m
Profitto lordo	-DKK 627.26m
Altre spese	DKK 425.28m
Guadagni	-DKK 1.05b

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

Feb 20, 2025

Utile per azione (EPS)	-14.90
Margine lordo	-816.00%
Margine di profitto netto	-1,369.25%
Rapporto debito/patrimonio netto	3.2%

Come si è comportato ZEAL nel lungo periodo?

Vedi performance storica e confronto

ZEAL Panoramica delle azioni

Premi

Analisi del rischio

Zealand Pharma A/S Concorrenti

CPSE:GMAB

DKK 93.0b

CPSE:BAVA

DKK 14.6b

CPSE:BIOPOR

DKK 696.9m

CPSE:HLUN B

DKK 41.5b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Recent updates

Employee Representative Director recently sold kr.1.3m worth of stock

Forecast to breakeven in 2025

Analyst Forecasts For Zealand Pharma A/S (CPH:ZEAL) Are Surging Higher

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Zealand Pharma A/S to Report Q1, 2025 Results on May 08, 2025

Consensus EPS estimates fall by 14%

Zealand Pharma Provides U.S. Regulatory Update on Dasiglucagon in Congenital Hyperinsulinism

Insufficient new directors

Rock star Growth Puts Zealand Pharma (CPH:ZEAL) In A Position To Use Debt

President & CEO recently sold kr.31m worth of stock

Consensus revenue estimates fall by 11%

Things Look Grim For Zealand Pharma A/S (CPH:ZEAL) After Today's Downgrade

Zealand Pharma A/S (CPH:ZEAL) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 40%

Zealand Pharma A/S Appoints Eric Cox as Chief Commercial Officer, Effective August 5, 2024

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 6.257 billion.

Zealand Pharma A/S Announces Positive Topline Results from the Phase 1B 16-Week Multiple Ascending Dose Clinical Trial with Long-Acting Amylin Analog Petrelintide

Zealand Pharma A/S Announces Boehringer Ingelheim Will Present Positive Results from Phase 2 Trial with Survivalodutide in MASH at EASL

Zealand Pharma Announces Topline Results from the Mechanistic Investigator-Led Dream Trial with Low Doses of GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide

Zealand Pharma A/S Approves Appointments to the Board

Zealand Pharma A/S Announces Board Changes

Zealand Pharma A/S Announces Boehringer Ingelheim Survodutide Phase 2 Trial Shows 83% of Adults Treated a Statistically Significant Improvement of Metabolic Dysfunction-Associated Steatohepatitis

Zealand Pharma A/S, Annual General Meeting, Mar 20, 2024

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S has filed a Follow-on Equity Offering in the amount of DKK 1.45362 billion.

Zealand Pharma A/S Appoints Enrique Conterno and Elaine Sullivan as Board Observers

Zealand Pharma A/S to Report Q1, 2024 Results on May 16, 2024

Boehringer Ingelheim and Zealand Pharma A/S Announces Initiation of Three Phase III Trials

Zealand Pharma A/S Announces Designation of Priority Review by the US FDA for Dasiglucagon in Congital Hyperinsulinism

Zealand Pharma A/S Announces Positive Results from Part 1 of Multiple Ascending Dosing Trial with Amylin Analog ZP8396

Zealand Pharma Submits Marketing Authorization Application for Dasiglucagon for Treatment of Severe Hypoglycemia in Diabetes to the European Medicines Agency

Boehringer Ingelheim and Zealand Pharma A/S Announces Phase II Trial Showed 14.9% Weight Loss in People Living with Obesity or Unveil

Zealand Pharma A/S has completed a Follow-on Equity Offering in the amount of DKK 786.05 million.

Zealand Pharma A/S Announces Positive Results from Phase 3 Trial of Glepaglutide in Patients with Short Bowel Syndrome (Ease 1)

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism At the 60Th Annual Espe Meeting

Zealand Pharma A/S Announces Chief Financial Officer Changes

Zealand Pharma A/S Revises Revenue Guidance for the Full Year of 2022

Zealand Pharma Announces Voluntary Delisting of American Depositary Shares from the Nasdaq Global Select Market

Zealand Pharma A/S Presents Data from Phase 1 Trial of Dapiglutide and to Move into Phase 2 Trial for Obesity

Zealand Pharma Announces Appoints David M. Kendall, as Chief Medical Officer

Insufficient new directors

Consensus forecasts updated

Zealand Pharma A/S Announces Positive Top-Line Results from Its Second Phase 3 Clinical Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism

Zealand Pharma A/S (CPSE:ZEAL) entered into an agreement to acquire V-Go® Insulin Delivery Device from Zealand Pharma for $10 million.

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Price target decreased to kr.229

Zealand Pharma Announces CEO Changes

Auditors Are Concerned About Zealand Pharma (CPH:ZEAL)

Full year 2021 earnings: Revenues in line with analyst expectations

Consensus forecasts updated

Zealand Pharma A/S Announces Completion of Patient Enrollment in the Second Phase 3-Trial, 17103 in Children with Congenital Hyperinsulinism

Zealand Pharma Completes Enrollment in Ease-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome

Consensus forecasts updated

Zealand Pharma A/S announced that it expects to receive $200 million in funding from Oberland Capital Management LLC

Zealand Pharma Announces Successful Outcome of Phase 1B Clinical Trial with GLP1-GLP2 Dual Receptor Agonist, Dapiglutide

Price target decreased to kr.228

Third quarter 2021 earnings released: kr.4.61 loss per share (vs kr.5.76 loss in 3Q 2020)